Moleculin Biotech, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. The unaudited statements are consolidated and presented in thousands of dollars, except per-share data. Moleculin is a clinical-stage pharmaceutical company developing drug candidates for resistant cancers and viruses; it reported no revenue.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $4.620 million | $4.105 million |
| General and administrative expense | $2.422 million | $1.939 million |
| Total operating expenses | $7.074 million | $6.088 million |
| Net loss | $6.867 million | $4.445 million |
| Net loss per share, basic and diluted | $0.24 | $0.20 |
| Net cash used in operating activities | $4.805 million | $3.624 million |
| Cash and cash equivalents | $66.104 million | $70.903 million at Dec. 31, 2021 |
| Total current assets / current liabilities | $67.260 million / $4.834 million | $72.497 million / $3.622 million at Dec. 31, 2021 |
| Total liabilities | $6.136 million | $5.097 million at Dec. 31, 2021 |
Cash declined by $4.799 million during the quarter. Investing cash use was $6,000; there were no financing proceeds in Q1 2022. The company disclosed no conventional borrowings in the presented balance sheet; liabilities include a $1.252 million warrant liability and operating lease obligations. Gross margin is not meaningful because the company had no revenue. Management expects operating losses and negative operating cash flow for the next several years.
Changes and unusual items
- Net loss increased by $2.422 million year over year as operating expenses rose by $986,000. R&D expense increased by $515,000, attributed principally to greater clinical-trial activity, additional drug-product manufacturing, and a license termination fee. G&A expense increased by $483,000, mainly from regulatory legal services, consulting, and advisory fees.
- A $400,000 expense related to terminating certain Exploration Invest license agreements was recorded in Q1 2022.
- The gain from revaluing warrant liabilities fell to $160,000 from $1.577 million in Q1 2021, reducing the offset to operating losses. This noncash fair-value gain is sensitive to share-price movements.
- Q1 2021 financing included approximately $74.7 million net proceeds from stock sales and warrant exercises; no shares were issued in Q1 2022. Shares outstanding were 28,578,338 at March 31, 2022 and May 4, 2022, versus weighted-average shares of 21,808,565 in Q1 2021.
Outlook, developments, and risks
- Management said March 31 cash was expected to fund projected operating requirements into 2024, potentially including increased R&D spending. This estimate depends on clinical and preclinical activity and could change; the company cautioned that future financing may be needed and may not be available on acceptable terms.
- No formal revenue or earnings guidance was provided. The company’s strategy is to advance its candidates and seek licensing or strategic partners for development and commercialization.
- The filing describes six drug candidates across Annamycin, WP1066, and WP1122 portfolios; three had shown human activity in clinical trials. Subsequent to quarter-end, the company reported FDA IND clearance for a WP1066 study and Polish authorization to proceed with an Annamycin/Cytarabine study. These were reported developments, not Q1 financial results.
- Key risks include clinical-trial enrollment, safety and efficacy, regulatory approvals and timing, third-party manufacturing and supply, reliance on MD Anderson licenses, competition, intellectual-property protection, and the need for additional capital. The company disclosed potential license fees, milestone and royalty payments, including possible payments of up to $500,000 for certain Phase II or Phase III milestones and up to $600,000 for certain NDA or first-approval milestones.
- The company reported no legal proceedings. Management assessed disclosure controls as effective as of March 31, 2022, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the stated cash runway into 2024 remains supportable under actual trial spending, manufacturing costs, and any expansion of internally funded programs.
- Clinical-trial enrollment, regulatory status, timing, and reported results for Annamycin, WP1066, and WP1122, including which developments occurred after March 31.
- The terms and potential cash impact of MD Anderson and other license obligations, including the Exploration Invest termination payment.
- Future financing needs and potential dilution, given continuing losses, no revenue, and no Q1 2022 financing proceeds.
- The assumptions underlying the Level 3 warrant-liability valuation and its effect on reported noncash gains or losses.